Method of suppressing immune response by reducing intracellular content of glutathione in macrophages and monocytes
A method of suppressing immune responses, comprising administering to a patient in need thereof an effective amount of a composition comprising a substance capable of reducing the content of reductive glutathione in macrophages.
1. A method of treating gastrointestinal inflammatory disease, hepatitis, or hepatic cirrhosis, comprising administering to a subject in need thereof an effective amount of
(1) a cystine derivative represented by formula (I):
wherein
R 1 and R 2 , independently from each other, represent an alkyl group or an alkyl group substituted with a nitroxylbutyl group, and
R 3 and R 4 , independently from each other, represent an acyl group or a peptidyl group; and
(2) at least one of Il-4 or TGF-beta,
wherein administration of (1) and (2) (a) reduces the content of reductive glutathione in macrophages in the subject, (b) increases the capability of the macrophages to produce IL-6, and (c) decreases the capability of the macrophages to produce IL-12 and NO.
2. The method of claim 1 , wherein IL-4 is administered to the subject.
3. The method of claim 1 , wherein TGF-beta is administered to the subject.
4. The method of claim 1 , wherein the subject is suffering from gastrointestinal inflammatory disease.
5. The method of claim 1 , wherein the subject is suffering from hepatitis.
6. The method of claim 1 , wherein the subject is suffering from hepatic cirrhosis.
7. The method of claim 1 , wherein the subject is also suffering from rheumatoid arthritis.
8. The method of claim 1 , wherein the intracellular content of reductive glutathione is reduced to at most 0.1 nmoles of glutathione per 5×10 5 macrophage cells.
9. The method of claim 1 , wherein the alkyl group has 1 to 12 carbon atoms.
10. The method of claim 1 , wherein the acyl group has into 12 carbon atoms.
11. The method of claim 1 , wherein the peptidyl group has 1 to 10 amino acids.
12. A method of treating a cachectic condition caused by one or more conditions selected from the group consisting of cancers, diabetes, gastrointestinal inflammatory diseases, chronic rheumatoid arthritis, hepatitis, hepatic cirrhosis, hypersensitive interstitial pneumonia, pulmonary fibrosis, and autoimmune inflammatory diseases, comprising administering to a subject in need thereof an effective amount of a cystine derivative represented by formula (I):
wherein
R 1 and R 2 , independently from each other, represent an alkyl group or an alkyl group substituted with a nitroxylbutyl group, and
R 3 and R 4 , independently from each other, represent an acyl group or a peptidyl group, wherein at least one of R 3 and R 4 is a peptidyl group having into 10 amino acids,
wherein administration of the cystine deriviative (a) reduces the content of reductive glutathione in macrophages in the subject, (b) increases the capability of the macrophages to produce IL-6, and (b) decreases the capability of the macrophages to produce IL-12 and NO.
13. The method of claim 12 , wherein R 3 is a peptidyl group having into 10 amino acids.
14. The method of claim 12 , wherein R 4 is apeptidyl group having into 10 amino acids.
15. The method of claim 12 , wherein the intracellular content of reductive glutathione is reduced to at most 0.1 nmoles of glutathione per 5×10 5 macrophage cells.
16. The method of claim 12 , wherein the subject is suffering from chronic rheumatoid arthritis.
17. The method of claim 12 , further comprising administering IL-4 to the subject.
18. The method of claim 12 , further comprising administering TGF-beta to the subject.
19. The method of claim 12 , wherein the alkyl group has 1 to 12 carbon atoms.
20. The method of claim 12 , wherein the acyl group has into 12 carbon atoms.
21. The method of claim 12 , wherein the peptidyl group has 1 to 10 amino acids.
22. The method of claim 12 , wherein the acyl group is derived from a hydrocarbon carboxylic acid.